NLX-P101 Uses, Dosage, Side Effects and more

NLX-P101, gene therapy is developed by Neurologix to treat Parkinson’s disease. The gene is glutamic acid decarboxylase (GAD), whose product synthesizes the major inhibitory neurotransmitter in the brain, (gamma)-aminobutyric acid (GABA), and targets the subthalamic nucleus (STN), which is overactive in patients with Parkinson’s disease. NLX-P101 is being evaluated as a therapeutic drug when injected into this deep brain structure that is known to function abnormally in Parkinson’s patients.

Trade Name NLX-P101
Generic NLX-P101
Type
Groups Investigational
Therapeutic Class
Manufacturer
Available Country
Last Updated: January 7, 2025 at 1:49 am

Uses

Investigated for use/treatment in parkinson's disease.

Innovators Monograph

*** Taking medicines without doctor's advice can cause long-term problems.
Share